知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.019 seconds)

筛选除外

    BAFF selective binding compounds and related methods
    1.
    发明授权
    BAFF selective binding compounds and related methods 有权

    公开(公告)号：US11267894B2

    公开(公告)日：2022-03-08

    申请号：US16547221

    申请日：2019-08-21

    Applicant: Ossianix, Inc.

    Inventor： Julien Häsler ,  Julia Lynn Rutkowski

    IPC: C07K16/28 ,  C07K16/24 ,  A61K39/395 ,  A61K47/68 ,  G01N33/68 ,  C07K14/525 ,  C07K14/705 ,  C07K14/71 ,  A61K39/00

    Abstract: The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.

    BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
    2.
    发明申请
    BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS 审中-公开

    公开(公告)号：US20200024354A1

    公开(公告)日：2020-01-23

    申请号：US16547221

    申请日：2019-08-21

    Applicant: Ossianix, Inc.

    Inventor： Julien HÄSLER ,  Julia Lynn RUTKOWSKI

    IPC: C07K16/28 ,  G01N33/68 ,  C07K16/24 ,  A61K39/395 ,  A61K47/68

    Abstract: The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.

    TfR selective binding compounds and related methods
    4.
    发明授权
    TfR selective binding compounds and related methods 有权

    公开(公告)号：US10722576B2

    公开(公告)日：2020-07-28

    申请号：US15594632

    申请日：2017-05-14

    Applicant: Ossianix, Inc.

    Inventor： Julien Häsler ,  Julia Lynn Rutkowski ,  Krzysztof Bartlomiej Wicher

    IPC: C07K16/18 ,  A61K39/395 ,  C07K16/40 ,  C07K16/28 ,  C07K16/46 ,  C12N15/85 ,  A61K39/00 ,  G01N33/53

    Abstract: The present invention relates to peptides that bind with high specificity and which functionally interact with the transferrin receptor (“TfR”) and which may be used in making molecular vehicles that carry biomolecules across membranes, including, e.g., across the blood brain barrier or the gastrointestinal tract. TfR specific binding moieties may also be used alone or as components in specific molecules that target the transferrin/transferrin receptor transport system. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to TfR, compounds and compositions comprising a TfR specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a TfR specific VNAR binding moiety. Other uses for TfR specific VNAR binding moieties of the invention include, e.g., regulating the interaction of iron-charged transferrin with TfR (receptor cycling or cell surface presentation), such as may be therapeutic in treatment of certain cancer cells and tumors of various tissue types.

    Baff selective binding compounds and related methods
    5.
    发明授权
    Baff selective binding compounds and related methods 有权

    公开(公告)号：US10435474B2

    公开(公告)日：2019-10-08

    申请号：US15107921

    申请日：2014-12-22

    Applicant: Ossianix, Inc.

    Inventor： Julien Häsler ,  Julia Lynn Rutkowski

    IPC: C07K16/24 ,  A61K39/395 ,  C07K16/28 ,  G01N33/68 ,  A61K47/68 ,  C07K14/525 ,  C07K14/705 ,  C07K14/71 ,  A61K39/00

    Abstract: The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.

    BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
    6.
    发明申请
    BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS 审中-公开
    BAFF选择性结合化合物及相关方法

    公开(公告)号：US20160333103A1

    公开(公告)日：2016-11-17

    申请号：US15107921

    申请日：2014-12-22

    Applicant: OSSIANIX, INC.

    Inventor： Julien HÄSLER ,  Julia Lynn RUTKOWSKI

    IPC: C07K16/28 ,  G01N33/68 ,  A61K47/48

    CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/241 ,  C07K2317/20 ,  C07K2317/22 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6872

    Abstract: The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.

    Abstract translation: 本发明涉及以高特异性和亲和力结合B淋巴细胞刺激剂（“BAFF”）的肽拮抗剂，从而拮抗BAFF受体（“BAFF-R”）信号传导。 本发明更具体地涉及衍生自护理鲨的VNAR单链抗体，其结合BAFF，BAFF拮抗剂化合物和包含BAFF特异性VNAR结合部分的组合物，其制备方法，与体外或体内相关的诊断和治疗方法 B细胞消耗，例如治疗和/或预防其中有益于杀死或消耗B细胞的病理状况，障碍或疾病，例如包括系统性红斑狼疮（SLE），类风湿性关节炎（RA）或类风湿性关节炎（RA）或自身免疫疾病 多发性硬化症（MS），以及某些血液癌症，包括淋巴瘤，白血病和骨髓瘤。

    TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERS
    9.
    发明申请
    TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERS 有权

    公开(公告)号：US20210395381A1

    公开(公告)日：2021-12-23

    申请号：US17275911

    申请日：2019-09-13

    Applicant: Ossianix, Inc.

    Inventor： Krzysztof B. Wicher ,  Julia Lynn Rutkowski ,  Pawel Stocki

    IPC: C07K16/28 ,  A61K47/68 ,  G01N33/68 ,  G01N33/50 ,  C12N15/10

    Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain. The present invention relates to a transcytosis selection method to obtain VNARs against mammalian blood brain barrier (BBB) receptors using phage display libraries as well as against receptors found in other directional cell barrier systems like the gastrointestinal tract and other organs. The VNARs may be used alone or as components in compositions or as conjugates that target the particular receptor transport systems for delivery of therapeutics or diagnostics to the brain (in the case of BBB receptors) or other tissues.

Patent Agency Ranking